Wird geladen...
PHASE I TRIAL OF MOTEXAFIN GADOLINIUM AND DOXORUBICIN IN THE TREATMENT OF ADVANCED MALIGNANCIES
PURPOSE: To assess the safety, maximum-tolerated dose (MTD), and dose-limiting toxicities (DLT), of motexafin gadolinium (MGd), given in combination with doxorubicin, in patients with advanced solid tumors. STUDY DESIGN: The combination of MGd and doxorubicin was administered every 28 days (cycle 1)...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Format: | Artigo |
| Sprache: | Inglês |
| Veröffentlicht: |
2009
|
| Schlagworte: | |
| Online Zugang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3038176/ https://ncbi.nlm.nih.gov/pubmed/19997959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-009-9364-z |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|